Fig. 6

Pharmacological inhibition of IFN-I cascades impairs the anti-itch effects of STING agonism on opioid-induced acute itch and dermatitis-induce chronic itch in mice. A and B A selective TBK1 inhibitor BX795 (i.t., 0.1, 1 and 10 μg) was injected immediately after DMXAA (i.p., 20 mg/kg) treatment. ELISA assay showed the spinal concentrations of IFN-α and IFN-β at 1 h after DMXAA and BX795 treatment. n = 6 mice/group. C-E BX795 (i.t., 10 μg), anti-IFN-α (i.t., 300 ng) and anti-IFN-β (i.t., 300 ng) that were injected immediately after DMXAA (i.p., 20 mg/kg) treatment compensate the pruritus alleviation by DMXAA in three mouse models of morphine-induced itch (C), AEW-induced itch (D), and DCP-induced itch (E). n = 8 mice/group. Data are expressed as mean ± SD and analyzed by one-way ANOVA with Bonferroni post hoc test. n.s., not significant